EWEW
US • —
$90.46
P/E
48.21
PEG
—
FCF Yield
—
Rev Growth YoY
+13.8% YoY
Gross Margin
77.9%
Health Score
—
D/E Ratio
0.06
Confidence
LOW
Business Snapshot
Edwards Lifesciences operates in the structural heart disease medical device market, with a primary focus on transcatheter heart valve replacement therapies. The company is a well-established leader in the transcatheter aortic valve replacement (TAVR) space, competing against a handful of major med-tech firms. Its market capitalisation, revenue, and precise financial scale data are not available in this dataset, limiting the ability to assess its size relative to peers. A defining characteristic of the business is its high gross margin, a hallmark of its proprietary medical device technology.
Financial Health
Score: N/A Gross margin stands at a robust 77.9%, reflecting strong pricing power and a valuable product portfolio. Net margin (TTM) is reported at 17.4%, indicating solid profitability after all expenses...
Risk Assessment
- VALUATION — P/E of 48.21x is more than double the sector average of 22x, exposing the stock to de-rating risk if growth disappoints.
- EARNINGS QUALITY — Earnings growth declined 73.2% year-over-year, a severe drop that raises questions about profitability sustainability.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- FCF / CASH BURN — Free cash flow is negative or unavailable, preventing a cash-flow-based valuation assessment....
Score: N/A Gross margin stands at a robust 77.9%, reflecting strong pricing power and a valuable product portfolio. Net margin (TTM) is reported at 17.4%, indicating solid profitability after all expenses. The balance sheet is conservative, with a debt-to-equity ratio of just 0.06x and a current ratio of 3.72x, suggesting ample liquidity and minimal financial leverage. Return on equity is 10.6%, a reasonable return for shareholders but not exceptional. Free cash flow and FCF yield are not reported, making it impossible to assess the company's cash generation or capacity for reinvestment or dividends. Overall, the company shows strong profitability and a fortress-like balance sheet, but the absence of cash flow data represents a key gap in evaluating its financial health.
* VALUATION — P/E of 48.21x is more than double the sector average of 22x, exposing the stock to de-rating risk if growth disappoints. * EARNINGS QUALITY — Earnings growth declined 73.2% year-over-year, a severe drop that raises questions about profitability sustainability. * TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. * FCF / CASH BURN — Free cash flow is negative or unavailable, preventing a cash-flow-based valuation assessment.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives